Expanding the small molecule toolbox through novel applications of fluorinated alkenes
通过氟化烯烃的新颖应用扩展小分子工具箱
基本信息
- 批准号:10714822
- 负责人:
- 金额:$ 28.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAlkenesAnti-Bacterial AgentsAntibiotic ResistanceAntibiotic TherapyAntibioticsAreaAwardBacterial Drug ResistanceBacterial InfectionsBiologicalCell WallCellular StructuresChemicalsCollaborationsDisparateEnvironmentEnzymesEvolutionFosteringFutureGoalsHealthcare IndustryHeterocyclic CompoundsInternationalLearningLigandsMedicineMethodsMulti-Drug ResistanceNitrogenPostdoctoral FellowPropertyResearchScienceStructureUnited StatesUniversitiesWorkcostfascinateglobal healthgraduate studenthuman diseaseinnovationinsightmultidisciplinarynew chemical entitynovelprogramsprotein degradationrational designresistant strainscreeningskillssmall moleculetoolundergraduate student
项目摘要
New Methods and Chemical Tools Against Multi Drug-resistant Bacterial Infections
ABSTRACT
The central theme of our lab revolves around small molecules. We contribute to developing new methods and
strategies to access small molecules of biological and medicinal relevance and using them as tools to probe
biological questions or human diseases. This proposal outlines our ongoing efforts and future directions of two
seemingly disparate programs that we envision merging into a ligand-discovery platform using 19F NMR. One of
our research program's focus areas is on fluorinated alkenes with a fascinating chemical reactivity portfolio
primarily due to the polarity inversion feature. We are investigating the polarity inversion property of fluorinated
alkenes, which we recognize will solve the long-standing problem of regioselectivity in fluorinated heterocyclic
compounds. Our work demonstrated the applicability of FAs in generating regioselective access to nitrogen-
containing fluorinated heterocycles. The other research area is focused on seeking new chemical tools and
innovative strategies to address the evolution of antibiotic-resistance strains that have impeded antibiotic
treatment and rendered them ineffective, costing heavily on the healthcare industry. We are currently probing
the MraY enzyme, a key component of cell wall synthesis, using conventional structure-based rational design
strategy and unconventional discovery platforms of targeted protein degradation and 19F NMR-based ligand
screening. An R35 MIRA award would help accomplish our goals and enable the merger of our two research
themes. Successful completion of these studies will allow us to contribute broadly in gaining insights into the
function, structure, and mechanism of inhibition of antibacterial targets using fluorinated probes, small-molecule
degraders, and a 19F NMR-based screening platform. These studies will lead to antibacterials with new chemical
entities with novel mechanism of action that are urgently needed to replenish our arsenal of new and existing
antibiotics. An R35 MIRA award would also foster our existing and new collaborations within the university,
across the United States, and internationally. This research program will help the participating graduate, and
undergraduate students and postdoctoral scholars enhance and learn new skills in interdisciplinary sciences
while working in a highly collaborative and multidisciplinary environment.
对抗多重耐药细菌感染的新方法和化学工具
抽象的
我们实验室的中心主题围绕小分子。我们致力于开发新方法和
获取具有生物和医学相关性的小分子并将其用作探测工具的策略
生物学问题或人类疾病。该提案概述了我们正在进行的努力以及两个项目的未来方向
我们设想将看似不同的程序合并到使用 19F NMR 的配体发现平台中。之一
我们的研究计划的重点领域是具有令人着迷的化学反应组合的氟化烯烃
主要是由于极性反转特性。我们正在研究氟化物的极性反转特性
烯烃,我们认为这将解决氟化杂环中长期存在的区域选择性问题
化合物。我们的工作证明了 FA 在区域选择性获取氮方面的适用性
含有氟化杂环。另一个研究领域专注于寻找新的化学工具和
解决阻碍抗生素的抗生素耐药菌株进化的创新策略
治疗并使它们无效,给医疗保健行业带来沉重代价。我们目前正在探索
MraY酶是细胞壁合成的关键成分,采用传统的基于结构的理性设计
靶向蛋白质降解和基于 19F NMR 的配体的策略和非常规发现平台
筛选。 R35 MIRA 奖项将有助于实现我们的目标并实现我们两项研究的合并
主题。成功完成这些研究将使我们能够为深入了解
使用氟化探针、小分子抑制抗菌靶标的功能、结构和机制
降解剂和基于 19F NMR 的筛选平台。这些研究将导致使用新化学物质的抗菌剂
具有新颖行动机制的实体,迫切需要补充我们新的和现有的武器库
抗生素。 R35 MIRA 奖还将促进我们在大学内现有和新的合作,
遍及美国和国际。该研究计划将帮助参与的毕业生,并且
本科生和博士后学者增强和学习跨学科科学的新技能
在高度协作和多学科的环境中工作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sudeshna Roy其他文献
Sudeshna Roy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
催化CO2加氢为低碳烯烃的介孔碳限域Fe系催化剂的可控构筑与调控机制研究
- 批准号:22378345
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
催化烯烃直接硝化的P450过氧化物酶的分子设计与反应机制研究
- 批准号:22307125
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
受阻路易斯酸碱对催化的烯烃自由基氢官能团化反应研究
- 批准号:22301234
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
非共轭二烯烃选择性聚合催化剂的开发与应用研究
- 批准号:22371157
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
双金属限域ZSM-5分子筛及其在多碳烯烃芳构化中的应用研究
- 批准号:22371154
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Fusidic acid derivatization to enhance entry into Gram-negative pathogens
夫西地酸衍生化以增强进入革兰氏阴性病原体的能力
- 批准号:
9807473 - 财政年份:2019
- 资助金额:
$ 28.68万 - 项目类别:
Mechanisms of Enzymatic Vinyl Isonitrile Formation and Reprogramming of Isonitrilases and Iron/2-Oxoglutarate Desaturases
酶促乙烯基异腈形成的机制以及异腈酶和铁/2-氧戊二酸去饱和酶的重编程
- 批准号:
10174950 - 财政年份:2018
- 资助金额:
$ 28.68万 - 项目类别:
Mechanisms of Enzymatic Vinyl Isonitrile Formation and Reprogramming of Isonitrilases and Iron/2-Oxoglutarate Desaturases
酶促乙烯基异腈形成的机制以及异腈酶和铁/2-氧戊二酸去饱和酶的重编程
- 批准号:
10402382 - 财政年份:2018
- 资助金额:
$ 28.68万 - 项目类别:
Enantioselective Total Synthesis of Potential Anticancer Drug Bromophycolide A
潜在抗癌药物 Bromophycolide A 的对映选择性全合成
- 批准号:
8059398 - 财政年份:2011
- 资助金额:
$ 28.68万 - 项目类别:
Enantioselective Total Synthesis of Potential Anticancer Drug Bromophycolide A
潜在抗癌药物 Bromophycolide A 的对映选择性全合成
- 批准号:
8211838 - 财政年份:2011
- 资助金额:
$ 28.68万 - 项目类别: